Liqian Gao

Liqian Gao

Auto-generated profile, based on publicly available information

Liqian Gao

School of Pharmaceutical Sciences (Shenzhen) Shenzhen Campus of Sun Yat‐Sen University Shenzhen China

Research Focus & Metrics

Academic Career Length

19Years (2008-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 December 2019 in Nano Today
Verified
Journal Article
Closed access
Jianxun DingJianxun Ding
Jianxun Ding
JCJinjin Chen
Jinjin Chen
LGLiqian Gao
Liqian Gao
ZJZhongyu Jiang
Zhongyu Jiang
YZYu Zhang
Yu Zhang
XCXuesi Chen
Xuesi Chen

7 December 2020 in Chemical Society Reviews
Verified
Journal Article
Closed access
PDF file
LGLiqian Gao
Liqian Gao
WWWei Wang
Wei Wang
XWXuan Wang
Xuan Wang
FYFen Yang
Fen Yang
LXLiuxing Xie
Liuxing Xie
SYShao Q. Yao
Shao Q. Yao
Parkinson's disease (PD), as the second most common neurodegenerative disease, is caused by complex pathological processes and currently remains very difficult to treat. PD brings great distress to patients and imposes a heavy economic burden on society. The number of PD patients is growing as the aging population increases worldwide. Therefore, it is crucial to develop new tools for aiding the early diagnosis and treatment of PD. The significant pathological features involved in PD include the abnormal accumulation of α-synuclein, metal ion dyshomeostasis, oxidative stress, mitochondrial dysfunction and neurotransmitter deficiencies. In recent years, fluorescent probes have emerged as a powerful bioimaging tool with potential to help understand the pathological processes of PD via the detection and monitoring of pathological features. In this review, we comprehensively summarize the design and working mechanisms of fluorescent probes along with their applications in the detection of various PD biomarkers. We also discuss the current limitations of fluorescent probes and provide perspectives on how these limitations can be overcome to develop better fluorescent probes suitable for application in clinical trials in the future. We hope that this review provides valuable information and guidance for the development of new fluorescent probes that can be used clinically in the early diagnosis of PD and contributes to the development of efficient PD drugs in the future.

9 January 2019 in Frontiers in Pharmacology
Verified
Journal Article
Open access
QXQicai Xiao
Qicai Xiao
WZWangshu Zhu
Wangshu Zhu
WFWei Feng
Wei Feng
SLSu Seong Lee
Su Seong Lee
ALAlbert Wingnang Leung
Albert Wingnang Leung
CXChuan shan XU
Chuan shan XU
Background: Cancer has become a major disease endangering human health around the world. Conventional chemotherapy suffers from many side effects including pain, cardiotoxicity, hepatotoxicity, and renal toxicity. This review aims to describe a natural product of resveratrol as a chemoprotective and synergistic agent in the modulation of cancer chemotherapy. Methods: The publications were identified by comprehensive searching of SciFinder, PubMed, Web of Science, and our own reference library. Search terms included combinations of "resveratrol," "cancer," "natural products," "chemotherapy," and "side effects." Selection of material focused on resveratrol reducing the side effects on cancer chemotherapy. Results: Thirty one references were referred in this review to outline resveratrol as a potent chemoprotective and synergistic agent in cancer chemotherapy, including 22 papers for describing the chemoprotective effects, and 9 papers for illustrating the synergistic effects. Conclusion: This study provides a systematic summary of resveratrol serving as a potent chemoprotective and synergistic agent to reduce the associated-side effects and enhance the therapeutic outcomes in cancer chemotherapy. Further studies in terms of resveratrol on a large amount of preclinical tests and clinical trials are highly demanded.

1 August 2020 in European Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
BSBigyan Sharma
Bigyan Sharma
LXLiuxing Xie
Liuxing Xie
FYFen Yang
Fen Yang
WWWei Wang
Wei Wang
QZQuanming Zhou
Quanming Zhou
WDWenbin Deng
Wenbin Deng

7 October 2015 in Current Pharmaceutical Design
Verified
Journal Article
Closed access
ZYZhiqiang Yu
Zhiqiang Yu
Quan XuQuan Xu
Quan Xu
CDChenbo Dong
Chenbo Dong
SLSu Lee
Su Lee
LGLiqian Gao
Liqian Gao
JWJun Wu
Jun Wu
Molecular hydrogels have been widely explored in various biomedical applications, such as cell culture, tissue engineering and drug delivery. Peptide-based hydrogel nanoparticles represent a promising alternative to current drug delivery approaches and cell carriers for tissue engineering, due to their encapsulation stability, water solubility and biocompatibility. This review focuses on recent advances in the use of self-assembling peptide nanogels for applications in drug delivery. We firstly introduce a self-assembly mechanism for small molecules used in the peptide hydrogel, and then describe recent methods for controlling the assembly of molecular hydrogelations. A particular emphasis is placed on recent advances in the use of different types of peptide hydrogels as drug delivery carriers. Lastly, the current challenges and future perspectives for self-assembling peptide hydrogels in drug delivery applications are discussed.

11 January 2022 in Chemical Science
Verified
Journal Article
Open access
PDF file
JQJunjie Qin
Junjie Qin
WWWei Wang
Wei Wang
LGLiqian Gao
Liqian Gao
SYShao Q. Yao
Shao Q. Yao
POC diagnostics are driven by the rapid advances in CRISPR, electrochemical and optical biosensors. Related emerging strategies are described and discussed from the perspective of facilitating the practical application of biosensors in POC testing.